Alert Issued About Capecitabine (Xeloda) and Fatal Skin Reactions


An advisory from Health Canada indicates that the chemotherapy drug capecitabine (Xeloda) is being associated with potentially fatal skin reactions.

The U.S. FDA has approved capecitabine for the treatment of metastatic colorectal and breast cancer. Recently, the agency approved a generic version of the drug manufactured by Teva Pharmaceuticals.

Severe side effects

Officials from Health Canada reported in a letter to health professionals that "very rare cases of severe cutaneous reactions such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), in some cases with fatal outcome, have been reported during treatment with [capecitabine]."

They cited some signs and symptoms to look out for as well, including:

  • Flu-like symptoms
  • Fever
  • Skin itching
  • Painful red or purplish skin rash that spreads, blisters and eventually causes the skin to shed
  • Mouth sores
  • Eye burning
  • Discharge

These skin reactions are being considered so severe that any patient taking this medication who develops any of the listed symptoms ought to contact his or her doctor or health care team immediately.

Source: Medscape


The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational purposes and does not constitute the practice of medicine. We encourage all visitors to see a licensed physician or nutritionist if they have any concerns regarding health issues related to diet, personal image and any other topics discussed on this site. Neither the owners or employees of nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.